Press release
Eskag Pharma Introduces Liposomal Supplement Line for Advanced Nutrient Delivery
Kolkata, India - April 6, 2025 - Eskag Pharma Pvt. Ltd., a trusted name in pharmaceutical and nutraceutical manufacturing, has introduced a new range of liposomal supplements designed to support better nutrient absorption and bioavailability.The development of this product line reflects Eskag Pharma's ongoing investment in advanced health technologies. Liposomal supplements are formulated to encapsulate nutrients within lipid-based structures, enabling more efficient delivery to the bloodstream compared to conventional tablets or capsules.
The initial launch includes:
Liposomal Vitamin C - To help support immune function
Liposomal Iron - A gentle option for individuals with iron deficiency
Liposomal Magnesium - Aids muscle health and relaxation
Liposomal Glutathione - Supports antioxidant defense and detox pathways
These supplements are well-suited for individuals who seek enhanced absorption or have difficulty tolerating traditional supplement forms. The new formulations align with global trends in personalized wellness and bioavailable nutrition.
Eskag Pharma's manufacturing facility in Haridwar, India, is WHO-GMP certified and adheres to international standards. The company serves global markets including Africa, Latin America, and Southeast Asia with a focus on third-party manufacturing, quality assurance, and compliance.
SUITE NO.804 & 805, AG-112, SECTOR-II, BAISHAKHI, Bidhannagar, Kolkata, West Bengal 700091
Established in 1977, Eskag Pharma is a pharmaceutical formulation company based in Kolkata, India. With over four decades of expertise, the company delivers end-to-end contract manufacturing services, specializing in tablets, capsules, syrups, injectables, and nutraceuticals. Eskag partners with clients globally to offer scalable production, customized packaging, and regulatory documentation support.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eskag Pharma Introduces Liposomal Supplement Line for Advanced Nutrient Delivery here
News-ID: 4001746 • Views: …
More Releases for Liposomal
Rising Prevalence Of Cancer Fuels Growth In Liposomal Doxorubicin Market: A Sign …
The Liposomal Doxorubicin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Liposomal Doxorubicin Market Size and Projected Growth Rate?
The liposomal doxorubicin market has also shown strong growth in recent years. It is expected to grow from $1.23 billion in 2024 to $1.32…
Key Trend Reshaping the Liposomal Drug Delivery Devices Market in 2025: Strategi …
What industry-specific factors are fueling the growth of the liposomal drug delivery devices market?
The global increase in cancer cases is expected to bolster the liposomal drug delivery devices market in the future. These delivery systems offer targeted treatments for cancer through radiation therapy, chemotherapy, and surgical resection. For example, data from UK-based charity, Macmillan Cancer Support, in June 2022, revealed a cancer prevalence of 3 million in 2022, which is…
Leading Growth Driver in the Liposomal Doxorubicin Market Outlook in 2025: Risin …
What Are the Market Size and Growth Forecast for the Liposomal Doxorubicin Market?
Recent years has seen a significant increase in the market size of liposomal doxorubicin. This growth will continue from $1.23 billion in 2024, skyrocketing to $1.32 billion the following year, presenting a compound annual growth rate (CAGR) of 7.2%. The unprecedented growth observed in the historical stretch can be ascribed to factors such as advanced liposome formulations, beneficial…
Liposomal NMN: The Ultimate Solution for Anti-Aging
Liposomal NMN by Genuine Purity stands out in the crowded field of anti-aging product with its advanced formulation designed to boost NAD+ levels effectively. NMN, or Nicotinamide Mononucleotide, is a precursor to NAD+ (Nicotinamide Adenine Dinucleotide), a critical coenzyme involved in numerous cellular processes, including energy metabolism and DNA repair. Genuine Purity's liposomal delivery system ensures that NMN is absorbed efficiently, maximizing its benefits. [https://bit.ly/3VvcRMx]
The liposomal encapsulation technology used in…
Liposomal Supplements Market Research Report 2023
Liposomal Supplements Market
The global Liposomal Supplements market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-31J7848/Global_and_China_Liposomal_Supplements_Market_Insights_Forecast_to_2027
North American market for Liposomal Supplements is estimated to increase from $ million in 2023 to reach $ million by 2029,…
Liposomal Supplements Market Research Report 2023 - valuates reports
The global Liposomal Supplements market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Liposomal Supplements is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of %…